List of Excipients in Branded Drug ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

Generic Drugs Containing ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

Company	Ingredient	NDC	Excipient
Larken Laboratories Inc	acetaminophen, caffeine and dihydrocodeine bitartrate	68047-720	CELLULOSE, MICROCRYSTALLINE
Larken Laboratories Inc	acetaminophen, caffeine and dihydrocodeine bitartrate	68047-720	CROSPOVIDONE
Larken Laboratories Inc	acetaminophen, caffeine and dihydrocodeine bitartrate	68047-720	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSPOVIDONE
2	MAGNESIUM STEARATE

Excipient Strategy and Commercial Opportunities for Acetaminophen, Caffeine, Dihydrocodeine Bitartrate

Last updated: March 2, 2026

What is the current formulation landscape for the combination of acetaminophen, caffeine, and dihydrocodeine bitartrate?

This combination addresses pain, alertness, and opioid effects. Market strategies focus on optimizing excipient profiles to enhance stability, bioavailability, and patient compliance, while regulatory environments influence formulation choices.

What are the typical excipients used in this combination product?

• Binders and fillers: Microcrystalline cellulose, lactose, starch
• Disintegrants: Croscarmellose sodium, sodium starch glycolate
• Lubricants: Magnesium stearate, stearic acid
• Flavor agents: Vanilla, citrus extracts
• Preservatives: Sodium benzoate (if liquid)
• Flavor masking agents: To offset bitterness from dihydrocodeine

How do formulation considerations impact commercial viability?

Stability

Acetaminophen and dihydrocodeine are prone to degradation. Use of antioxidants (e.g., ascorbic acid) and buffered systems prolong shelf life.

Bioavailability

Caffeine’s solubility favors rapid absorption. Excipients such as sodium lauryl sulfate can enhance dissolution, improving onset.

Tolerance and Compliance

Taste-masking agents and convenient dosage forms, such as orally disintegrating tablets (ODTs), increase patient adherence.

Manufacturing implications

Selection of excipients influences process complexity, yield, and cost. High-potency opioids demand strict control to avoid contamination.

What are potential commercial opportunities associated with excipient innovation?

Novel excipient development

• Use of superdisintegrants for immediate-release formulations
• Incorporation of mucoadhesive agents for sustained or buccal delivery

Platform development

• Ready-to-use formulations with standardized excipients streamline manufacturing
• Modular excipient systems adaptable to other combination drugs

Regulatory advantages

• Excipient compatibility with regulatory guidelines lowers approval barriers
• Use of Generally Recognized as Safe (GRAS) excipients facilitates market entry

Market expansion

• Customizable formulations targeting specific populations (e.g., pediatrics, elderly)
• Alternate delivery routes (e.g., film, wafer) open new channels

What are key regulatory considerations?

• Compatibility and stability testing per ICH Q8 guidelines
• Documentation of excipient safety and interactions
• Potential restrictions on opioid excipients in certain jurisdictions

What are competitive pressures and patent landscape implications?

Exclusive patents on specific excipient compositions or novel delivery forms can provide market barriers. Conversely, off-patent formulations with optimized excipient profiles can compete on price.

---

Key Takeaways

• Excipient choice directly affects the stability, bioavailability, and compliance of acetaminophen, caffeine, and dihydrocodeine formulations.
• Innovation in excipient technology can create differentiation and expand market share.
• Regulatory compliance with stability and safety standards remains critical in formulation development.
• Manufacturing strategies must balance cost, complexity, and quality control.
• Market opportunities include pediatric formulations, alternative delivery systems, and tailored combination therapies.

---

FAQs

Q1: What excipients enhance the bioavailability of caffeine in combination products?

Sodium lauryl sulfate and povidone improve dissolution and absorption rates.

Q2: Are there regulatory limits on excipient use in opioid-containing medications?

Yes. Restrictions depend on jurisdictions, with certain excipients prohibited or limited in some markets due to safety concerns.

Q3: How can formulation strategies improve patient compliance?

Taste-masking agents, controlled-release forms, and convenient dosage forms like thin films increase adherence.

Q4: What are common challenges in formulating dihydrocodeine-based products?

Ensuring stability, minimizing degradation, controlling opioid release rates, and complying with strict handling regulations.

Q5: What role does excipient innovation play in market differentiation?

It enables faster onset, improved tolerability, and novel delivery forms, providing competitive advantages.

---

References

1. ICH Guidelines for Stability Testing (Q1A(R2)). International Council for Harmonisation. 2003.
2. U.S. Food and Drug Administration. Excipient Guidance for Industry. 2015.
3. European Medicines Agency. Reflection Paper on Safety and Efficacy of Excipients. 2018.
4. Pharmacopoeia Standards for Acetaminophen and Opioids. USP. 2021.
5. Market Research: Global Pain Management Market. ReportLinker. 2022.